Attenuated Dengue Virus PV001-DV Induces Oncolytic Tumor Cell Death and Potent Immune Responses

Author:

Goldufsky Josef W.1,Daniels Preston1,Williams Michael D.2,Gupta Kajal1,Lyday Bruce3,Chen Tony4,Singh Geeta4,Kaufman Howard L.5,Zloza Andrew1,Marzo Amanda Lee1

Affiliation:

1. Rush University Medical Center

2. Rush University Rush Medical College

3. Primevax Immunology-Oncology

4. Primevax Immunology-Oncology Inc

5. Massachusetts General Hospital

Abstract

Abstract Background Viral therapies developed for cancer treatment have classically prioritized direct oncolytic effects over their immune activating properties. However, recent clinical insights have challenged this longstanding prioritization and have shifted the focus to more immune-based mechanisms. Through the potential utilization of novel, inherently immune-stimulating, oncotropic viruses there is a therapeutic opportunity to improve anti-tumor outcomes through virus-mediated immune activation. PV001-DV is an attenuated strain of Dengue virus (DEN-1 #45AZ5) with a favorable clinical safety profile that also maintains the potent immune stimulatory properties characterstic of Dengue virus infection. Methods In this study, we utilized tumor killing and immune multiplex assays to examine the anti-tumor effects of PV001-DV as a potential novel cancer immunotherapy. Results In vitro assays demonstrated that PV001-DV possesses the ability to directly kill human melanoma cells lines as well as patient melanoma tissue ex vivo. Importantly, further work demonstrated that, when patient peripheral blood mononuclear cells (PBMCs) were exposed to PV001-DV, a substantial induction in the production of apoptotic factors and immunostimulatory cytokines was detected. When tumor cells were cultured with the resulting soluble mediators from these PBMCs, rapid cell death of melanoma and breast cancer cell lines was observed. These soluble mediators also increased dengue virus binding ligands and immune checkpoint receptor, PD-L1 expression. Conclusions The direct tumor-killing and immune-mediated tumor cytotoxicity facilitated by PV001-DV contributes support of its upcoming clinical evaluation in patients with advanced melanoma who have failed prior therapy.

Publisher

Research Square Platform LLC

Reference69 articles.

1. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma;Andtbacka RH;J Clin Oncol,2015

2. Immunogenic cell death in cancer and infectious disease;Galluzzi L;Nat Rev Immunol,2017

3. Chaurasiya S, Fong Y, Warner SG. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.Cancers (Basel), 2020. 12(6).

4. Immune System, Friend or Foe of Oncolytic Virotherapy?;Filley AC;Front Oncol,2017

5. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses;Ikeda K;Nat Med,1999

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3